SUMMARY A dose-escalation study was performed in 27 patients to determine the highest safe and potentially optimal dose of naloxone for treatment of acute cerebral ischemia. All patients received a bolus of naloxone followed by a continuous 24 hour infusion at an hourly rate 50% of the bolus. Loading doses ranged from 2.5 to 200 mg/m 2 . Total patient doses ranged from 52.3 to 4978 mg. No major dose-related side effects occurred. This study was not designed to determine naloxone's efficacy in stroke, but transient or sustained improvement was observed in 13 patients. Three patients' neurological condition worsened within three hours after the naloxone was discontinued. Our experience suggests that further therapeutic trials of naloxone are worthwhile.
Two patients had subjective improvement, 2 deteriorated and 15 remained stable. Fallis et al 4 administered 0.4 to 12 mg of naloxone or placebo one hour apart to 15 patients in a double-blind manner. No significant response to naloxone was noted. In another report, 3 of 13 patients given 0.4-0.8 mg of naloxone within 24 hours of ictus improved. 3 In another series, no difference was found between 20 patients treated with 1.2 mg of naloxone and 20 patients given placebo. 6 Recently, Percy et al 7 found improvement in 2 of 5 patients given 25.2 mg of naloxone within 12 hours of onset of ischemia.
The results of these clinical studies are inconclusive. Few patients have been treated and delays before treatment have been up to two weeks. Some patients with cerebral hemorrhage were treated. In addition, the optimal dose of naloxone for treatment of acute cerebral infarction in patients has not been determined. It is likely that doses much larger than those previously given will be required. Furthermore, sustained treatment may be required since the short half-life of naloxone makes it unlikely that a single bolus is adequate to ameliorate cerebral ischemia.
In designing a therapeutic trial, an adequate and safe dose must be determined. This is an essential first step before carrying out a controlled treatment study. While conventional doses of naloxone are safe, the safety of large doses is unknown. In particular, the safety of large-dose infusions of naloxone in a population of acutely-ill, mainly elderly patients must be established. We, therefore, completed a dose-escalation study of naloxone in patients with acute cerebral ischemia with the intent of utilizing the highest reasonably tolerated dose for a future study of efficacy.
Methods
Patients between the ages of 35 and 85 years with acute or progressing infarction were recruited. Patients with large artery atherosclerotic occlusions, large artery embolic occlusions (artery-to-artery or cardiac sources) or small artery (lacunar) infarctions of the brainstem, cerebellum or cerebral hemisphere were treated. Diagnoses were based on the clinical criteria developed for The Harvard Cooperative Stroke Registry; 8 an admitting diagnosis of large artery atherothrombotic occlusion was made if the patient had a gradual or stuttering course, history of previous transient ischemic attacks, and evidence of atherosclerosis by history or examination. Lacunar infarction was diagnosed if the patient had the abrupt or gradual onset of
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one of the traditional lacunar syndromes, no headache and no disturbance in consciousness. Embolism was diagnosed if the patient had the sudden onset of neurological signs, usually without warning, and a clinically apparent cardial or atherosclerotic embolic source. Treatment began within 48 hours of onset or latest progression of the stroke. Patients with transient ischemic attacks, cerebral hemorrhage, coma, hemorrhagic infarction or cerebral vasculitis were excluded. Also excluded were patients who had a history of convulsions, recent myocardial infarction, hypotension, or uncontrollable hypertension. No pregnant patients were treated. Past history of major psychiatric diseases, opiate or substance abuse, or other active cormorbid diseases that would interfere with potential response to therapy were exclusions.
Patients had CT before entry to eliminate hemorrhage. Baseline laboratory evaluation included: chest roentgenography, electrocardiogram (ECG), complete blood count, platelet count, blood fibrinogen, prothrombin time, partial thromboplastin time, blood glucose, serum electrolytes, serum creatine kinase and serum chemistry panel. Results were used to detect exclusion criteria and for comparison with subsequent studies.
Consent was obtained from the patient or family members. A bolus loading dose of naloxone was given at a rate not to exceed 10 mg/m 2 /min by a physician. A 24 hour continuous infusion immediately followed at an hourly rate that was 50% of the bolus dose (table 1) . Three patients were treated at each of nine dose levels. Escalation to a higher dose level did not happen until there was satisfactory completion of treatment of all patients at a previous level. Naloxone was donated by DuPont to us in a concentration of 10 mg/ml. It was added to normal saline for the maintenance infusion.
Other treatment consisted of bed rest, supplemental oxygen (2 liters/minute via nasal prongs) and intravenous saline to maintain urinary output. No food or glucose-containing fluids were given during the treatment period. Cardiac monitoring and frequent mea- n. m.
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DC. surements of vital signs were performed. Pretreatment drugs were continued; while additional new therapies, such as anticoagulants, were avoided.
Neurological and medical assessments were performed before treatment; at completion of the bolus; at 20 minutes, 1 hour, 6 hours, 12 hours and 24 hours respectively. Examinations were done 2 and 24 hours after completion of the infusion, at 7-10 days and again at 1 and 3 months. A neurological assessment flow sheet containing a glossary of definitions of neurological signs was used. The neurological assessments and glossary that we used will be a subject of a separate report. Assessed parameters are listed in table 2. A composite stroke scale was not used. Follow-up assessments included performance and placement, location in the community, and degree of recovery.
Laboratory studies were obtained at the end of the infusion and at 7-10 days. CT was repeated at 7-10 days after treatment and 3 months. CT analysis included assessments for mass effect, edema, shift of midline structures, cortical atrophy, enlarged ventricles of hypodense lesions of the stroke. Lesions were localized to arterial distributions and anatomical sites using standardized templates. All data were transmitted to Mathematical Statistics, BFSB, IRP, NINCDS for management and analysis.
Patient Population and Results
From May 13, 1984 , through September 26, 1984, the 9 dose levels were completed and 27 patients were treated (table 3) . Eleven patients were treated in Cincinnati and 16 in Iowa City. Thirty-five patients in Cincinnati were screened but had reasons for exclusion, while 20 potential subjects were excluded in Iowa City. Patient acceptance was impressive. Despite an imposing consent form, patients and families consistently opted for treatment with naloxone.
The patients' average age was 67 years (range: 40-84). Sixteen patients were men, 11 were women. Infarction was attributed to cardiac embolism in 5 patients, small artery (lacunar) occlusion -7, large artery atherothrombotic occlusion -11 and atheroembolic occlusion -4. Average interval from onset of symptoms until treatment was 14.5 hours (range: 3.5-83.2). Average interval from the most recent symptom before treatment was 8.0 hours (range: 0.5-15.5). Seventeen patients were treated within 12 hour of their most recent symptom and 20 were treated within 24 hours. Infarction involved the left hemisphere in 15 patients, the right hemisphere in 10 and brainstem in 2 (table 3) . Seven patients had diabetes mellitus and 10 had symptomatic coronary artery disease. Cardiac etiologies of cerebral embolism were atherosclerotic heart disease with atrial fibrillation in 4 patients and rheumatic mitral stenosis with atrial fibrillation in one. Baseline CT was normal in 13 patients; hypodense lesions thought to be new ischemic lesions were detected in 14.
The total dose of naloxone administered per patient ranged from 52.3 to 4978 mg (table 4) . Electrocardiographic changes during the nineteenth hour of infusion lead to precautionary discontinuation of naloxone in one patient. These changes, frequent premature ventricular contractions and bigeminy, were not attributed to toxicity of naloxone. The other 26 patients completed the 24 hour infusion.
Loading doses and maintenance infusions were tolerated without major complications (table 5) . Nausea, vomiting or retching occurred in 12 patients but 7 had these symptoms before treatment; no relationship to dosage was noted. •Same = neurological condition unchanged from admission; improved = neurological condition improved in interval; maintained = neurological condition unchanged in interval but better than admission; worse = neurological condition worsened in interval.
tPerformance: Ind = independent; mild I = mild impairment; MI = moderate impairment; SI = severe impairment.
confusion were seen in tVvo patients, but there was no relationship to dosage. No convulsions occurred. Increased muscle tone of the paralyzed limbs was noted in a few patients. Fourteen patients had partial or complete, temporary or sustained resolution of neurological deficits during treatment (table 4) . At the lowest bolus dose, one patient had improvement in her neurological status, but the signs recurred during the maintenance infusion. At all levels, improvement in neurological function accompanied the bolus dose in 10 patients. At the end of the maintenance infusion, 10 patients had improved. Three of the patients who improved with treatment worsened within three hours after the naloxone was discontinued. During the last 12 hours of the infusion, one patient deteriorated beyond her condition on admission. The remaining 13 patients were unchanged. No patients died during the treatment period. Twenty of 26 CT examinations done on days 7-10 were abnormal. No hemorrhages were found. Four patients died subsequent to their cerebral infarctions at 4, 6, 36 and 37 days after treatment. One patient died of refractory cerebral edema and transtentorial herniation, another died a cardiovascular death that was secondary to her neurological event. Two patients died of sepsis 36 and 37 days after treatment. No deaths were attributed to the side effects of naloxone.
At one month after treatment, 3 patients had completely recovered, 13 were partially improved, 8 were stable and 1 was worse. Fifteen patients were at home, 1 was in a minimal care facility, 2 were in skilled nursing facilities, 4 were in hospitals and 3 were at rehabilitation centers. Patient performances at one month were: independent -7, mild impairment -4, moderate impairment -9, and severe impairment -5.
Discussion
Drugs that antagonize the effects of neuropeptides, in particular endorphins, may be valuable for treatment of acute cerebral infarction. Naloxone is the drug that has received the most attention. Besides its opiate receptor antagonist functions, naloxone also has cellular effects that may be important in treatment of cerebral infarction. It alters transmembrane calcium flux and affects lipid peroxidation. 9 Naloxone may also have antioxidant actions.
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In doses much larger than those required to reverse the pharmacological actions of opiates, naloxone has cardiovascular effects. It increases myocardial contractility, cardiac output, heart rate and systolic and mean arterial pressures." It blocks the cerebral arterial vasoconstrictive effects of norepinephrine. 12 In high concentrations, naloxone produces vasodilation and increases cerebral blood flow.
12 Naloxone may also prevent cerebral edema. 13 Naloxone must be given parenterally and has a plasma half-life of approximately 60 minutes.'" Brain concentrations of naloxone parallel serum levels and brain penetration is high.
14 The rapid falls of brain and blood levels of naloxone after a single dose necessitates a constant infusion of the drug if sustained action is to be achieved. Previous clinical trials have not included a prolonged infusion.
While animal studies of naloxone in treatment of acute cerebral infarction provide conflicting results, 13 '
15~19 the dosage of naloxone required for a favorable impact is at least 2-5 mg/Kg. 20 These doses are many times higher than that conventionally used. They also far exceed the doses used in previous clinical studies in infarction.
Previous clinical reports have not proved or disproved the effectiveness of naloxone in treatment of cerebral infarction. The question of its value remains unanswered. Large doses (2-5 mg/Kg) of naloxone may be useful. However, before a controlled trial can be performed, the safety of large doses of naloxone in patients with cerebrovascular disease must be established. A dose-escalation study is the best method to accomplish this. We found naloxone to be a very safe drug, even using doses that are 10,000 times that usually given to reverse opiate overdoses.
Behavioral effects of single high doses of naloxone in normal subjects were studied by Cohen et al. 21 With 2-4 mg/Kg doses of naloxone, most subjects had nonspecific complaints such as "rush" or "buzz", tingling, yawning or dizziness. Some subjects became tense, hostile, anxious, confused or bewildered. Although we specifically queried for these syptoms, only 2 patients had these complaints. Nausea, anorexia or vomiting are common symptoms among subjects given large doses of naloxone. 21 We noted these symptoms in 12 patients but observed no relationship to dose. Additionally 7 patients had nausea or vomiting before treatment. It appears that naloxone may promote nausea and vomiting among patients with acute cerebral infarction.
Naloxone inhibits the functional activity of gammaaminobutyric acid.
10 Doses of naloxone of approximately 50 mg/Kg has been reported to induce generalized clonic convulsions. 22 One patient with an acute stroke had a convulsion following administration of a conventional dose of naloxone. 5 That patient was described as an alcoholic, who also had delirium tremens. None of our patients developed convulsions. Naloxone in doses up to 5 mg/Kg does not appear to be epileptogenic even in the presence of an acute cortical lesion.
Because naloxone may increase cellular metabolic demands, there is concern that its administration may aggravate infaraction. Only 1 of 27 patients worsened neurologically during treatment. Our experience suggests that naloxone does not worsen the consequences of acute infarction.
Large doses of naloxone may increase heart rate, systolic blood pressure and respiratory rate in normal subjects. 23 Similar responses were not seen in our patients. Naloxone does not produce major cardiovascular complications among patients with acute cerebral infarction.
The only biochemical or hematological abnormality observed during treatment was transient, mild elevations of bilirubin noted in 3 patients. No dose relationship was noted. The etiology of this laboratory change is not clear. Although it could be related to naloxone, the changes of bilirubin could be the result of fasting or the consequence of acute illness, since changes in bilirubin levels in acute stroke are not known. Further observation of this finding is necessary.
Naloxone in loading doses up to 160 mg/M 2 appears to be a maximally reasonably tolerated dose. A loading dose of 160 mg/M 2 can be used for further studies for effectiveness.
It was not the intent of this dose-escalation study to demonstrate any efficacy. However, certain observations are encouraging. In some patients, improvement was dramatic and rapid, a response that is atypical for acute cerebral infarction. Deterioration in 3 patients within hours after the naloxone was discontinued also suggests a possible therapeutic benefit. The results should provide an impetus for further investigation. We are currently treating more patients at the loading dose of 160 mg/M 2 . Further refinement of entry criteria and frequency of favorable responses can be used to develop a controlled trial.
